JGC
AUTL

J. Goldman & Co’s Autolus Therapeutics AUTL Stock Holding History

J. Goldman & Co’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-58,870
Closed -$391K – 350
2021
Q2 		$391K Buy
+58,870
New +$365K 0.02% 337

Other funds holding AUTL

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

J. Goldman & Co's AUTL Position: Q3 2021 in Review

J. Goldman & Co sold out of Autolus Therapeutics (AUTL) in Q3 2021, closing a stake of 58,870 shares — an estimated $391K sold.

J. Goldman & Co first reported a position in AUTL in Q2 2021 and held it in 1 quarter. The position peaked at $391K in Q2 2021. 59 funds tracked by Wall St. Rank hold AUTL as of Q3 2021.

  • J. Goldman & Co reported no remaining Autolus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • J. Goldman & Co sold 58,870 Autolus Therapeutics shares in Q3 2021, an estimated $391K.
  • J. Goldman & Co first reported a position in Autolus Therapeutics in Q2 2021 and held it in 1 quarter.
  • J. Goldman & Co's Autolus Therapeutics position peaked at $391K in Q2 2021.
  • 59 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2021.

Based on J. Goldman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.